REGENERON PHARMACEUTICALS, INC. (REGN) Overview
Healthcare • Nasdaq • CIK 0000872589
Loading...
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Market Cap
$98.47B
P/E (TTM)
20.4x
Rev Growth (TTM)
+18.6%
Net Margin (TTM)
28.5%
FCF Yield (TTM)
3.9%
FCF Margin (TTM)
22.6%
Figures as of September 30, 2026
Filings
Primary-source SEC disclosures, read end-to-end. SEC figures cite the filing they come from.
10-Q2026 Q32026-10-30source
8-KEarnings2026-10-30source
8-KEarnings2026-10-06source
8-KSep 20262026-09-30source
10-Q2026 Q22026-07-30source
What your agent reads
Investor Relations
Company-published material — management’s own words, not SEC-audited. Each source below is labeled so your agent knows what to verify.
Company-published, not SEC-audited
Earnings
Q3
17 days ago
8-K releaseRevenue
N/A
—
Net Income
$1.95B
+33.5%
EPS
N/A
—
Withheld (revenue): Withheld: the release's table was read from the wrong line, column or scale for this figure (for example a per-share figure, one line of revenue, or a table in thousands read as dollars), so it is not the release's figure for this line. Check the filing.
Most recent quarterly earnings snapshot
Cash Flow Health
Free Cash Flow8/8 positive
TTM$3.8B
Q3 '26
$1.5B+159%
Q2 '26
$572.8M-32%
FCF Margin
TTM22.6%
Q3 '2629.0%+117%
Sector: 3.3%Top 25%
OCF Margin
28.7%
OCF/NI1.01x
CapEx Coverage
4.8x
FCF Yield3.9%
FCF Growth (3Y)-6%
Cash Conversion Cycle
449 days
DSO: 133+DIO: 473−DPO: 157
Cash flow trends & capital efficiency
Capital Allocation
Total Shareholder YieldTTM
TTM3.5%
Div Yield0.4%
+Buyback (TTM)3.1%
Dividend & Payout Metrics
Dividend Yield (TTM)0.4%
FCF Payout Ratio10.0%
Free Cash Flow (TTM)$3.8B
Stock Repurchases (TTM)$3.0B
Capital Return / FCF89.3%
Shares Outstanding (YoY)-1.6%↓ Buyback
Est. Dividends Paid (TTM)$382.8M
Shows how management rewards shareholders
Valuation Metrics
Price-to-EarningsTTM
20.4x
Volatile
8Q: 16.8x-452%
Valuation Lenses
Earnings
20.4x
vs – sector
Cash Flow
23.8x
EV/FCF vs –
Growth-Adj
2.4xPEG
Expensive for growth
Quality-Adj
1.7P/E per %ROIC
ROIC: 12.2%
Shareholder Returns
Dividend
0.4%
Buyback
3.1%
Total Yield
3.5%
Market Cap$98.47B
EV$91.15B
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Multi-angle valuation analysis with sector context
Margins & Efficiency
ROIC 75th pctile
Profitability Cascade
Gross
85.8%
Operating
28.8%
Top 25% in sector
Net
28.5%
Margins Unknown
Return on Invested CapitalTTM
12.2%
Stable
+0.0% YoY8Q: 11.3%+5.8%
P25MedianP75
75th pctl (med: -8.0%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
24.4%
8Q: 23.8%
Asset Turnover
0.41x
8Q: 0.39x
Leverage (1+D/E)
1.06x
D/E: 0.06x
DuPont: 10.6% ≈ 12.2% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
3.19x
8Q:3.08x
+35.0%
Invested Cap Turn
0.84x
8Q:0.76x
+26.5%
CapEx Intensity
5.1%
8Q:4.6%
CapEx/Depreciation
1.99x
FCF vs Net Margin Gap-5.9 pts
Margin trends, ROIC, and capital efficiency
Balance Sheet & Solvency
Net Cash
Net Debt / EBITDA
Net Cash
(0.2x)Net Cash: $7.31B
Interest Coverage
104.2x
+Net cash position: $7.31B
+Strong interest coverage: 104.2x
Leverage Metrics
Debt-to-Equity
0.06x
Balance sheet risk & solvency analysis
Related Research
1 related post